NASDAQ:IRIXIRIDEX Stock Price, Forecast & News

$2.37

-0.02 (-0.84 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.31

Now: $2.37▼

$2.46

50-Day Range

$1.47

MA: $1.76▼

$2.58

52-Week Range

$1.22

Now: $2.37▼

$5.54

Volume18,151 shs

Average Volume47,381 shs

Market Capitalization$32.68 million

P/E RatioN/A

Dividend YieldN/A

Beta1.12

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
IRIDEX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, IRIDEX has a potential upside of 68.8% from its current price of $2.37.
Amount of Analyst Coverage
IRIDEX has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
IRIDEX has received 184 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IRIDEX has received 180 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IRIDEX has received 50.55% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote “Outperform” if you believe IRIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IRIDEX does not currently pay a dividend.
Dividend Growth
IRIDEX does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IRIDEX insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,410.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.00% of the stock of IRIDEX is held by insiders.
Percentage Held by Institutions
Only 34.79% of the stock of IRIDEX is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for IRIDEX are expected to grow in the coming year, from ($0.60) to ($0.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IRIDEX is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IRIDEX is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IRIDEX has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.93 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryN/A

SectorComputer and Technology

Current SymbolNASDAQ:IRIX

Previous Symbol

CUSIPN/A

CIK1006045

Webwww.iridex.com

Phone650-940-4700

Debt

Debt-to-Equity Ratio0.07

Current Ratio3.44

Quick Ratio2.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$43.45 million

Price / Sales0.75

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.65 per share

Price / Book1.44

Profitability

EPS (Most Recent Fiscal Year)($0.64)

Net Income$-8,810,000.00

Net Margins-17.71%

Return on Equity-31.74%

Return on Assets-21.17%

Miscellaneous

EmployeesN/A

Outstanding Shares13,790,000

Market Cap$32.68 million

Next Earnings Date8/4/2020 (Estimated)

OptionableNot Optionable

Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter.

IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

How has IRIDEX's stock been impacted by COVID-19 (Coronavirus)?

IRIDEX's stock was trading at $1.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IRIX shares have increased by 20.3% and is now trading at $2.37. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IRIDEX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IRIDEX.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for IRIDEX.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) posted its quarterly earnings results on Monday, May, 11th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. The medical equipment provider had revenue of $9.02 million for the quarter, compared to analysts' expectations of $9.51 million. IRIDEX had a negative return on equity of 31.74% and a negative net margin of 17.71%. View IRIDEX's earnings history.

What price target have analysts set for IRIX?

2 Wall Street analysts have issued twelve-month price objectives for IRIDEX's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate IRIDEX's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 68.8% from the stock's current price. View analysts' price targets for IRIDEX.

Has IRIDEX been receiving favorable news coverage?

News articles about IRIX stock have been trending very negative on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IRIDEX earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutIRIDEX.

Are investors shorting IRIDEX?

IRIDEX saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 31,600 shares, an increase of 65.4% from the April 30th total of 19,100 shares. Based on an average daily trading volume, of 35,700 shares, the short-interest ratio is currently 0.9 days. Approximately 0.3% of the company's shares are short sold. View IRIDEX's Current Options Chain.

Who are some of IRIDEX's key competitors?

Some companies that are related to IRIDEX include Edap Tms (EDAP), Fc Global Realty (FCRE), electroCore (ECOR), Reshape Lifesciences (RSLS), Helius Medical Technologies (HSDT), CHF Solutions (CHFS), Precision Optics (PEYE), Second Sight Medical Products (EYES), ENDRA Life Sciences (NDRA), Digirad (DRAD), Viveve Medical (VIVE), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), ReShape Lifesciences (RSLSD) and Guided Therapeutics (GTHP). View all competitors.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), SCYNEXIS (SCYX), AbbVie (ABBV), Agile Therapeutics (AGRX), CTI BioPharma (CTIC), Gilead Sciences (GILD), Trevena (TRVN), Allena Pharmaceuticals (ALNA) and Capstone Turbine (CPST).

Who are IRIDEX's key executives?

IRIDEX's management team includes the following people:

Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
Mr. Romeo R. Dizon, VP of Fin.
Ms. Leigh Salvo, Head of Investor Relations
Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors Inc. (6.38%), Perkins Capital Management Inc. (0.46%) and BlackRock Inc. (0.31%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Scott Shuda and William M Moore. View institutional ownership trends for IRIDEX.

Which major investors are selling IRIDEX stock?

IRIX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View insider buying and selling activity for IRIDEX.

Which major investors are buying IRIDEX stock?

IRIX stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., and Perkins Capital Management Inc.. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove, Scott Shuda, and William M Moore. View insider buying and selling activity for IRIDEX.

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $2.37.

How big of a company is IRIDEX?

IRIDEX has a market capitalization of $32.68 million and generates $43.45 million in revenue each year. The medical equipment provider earns $-8,810,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

What is IRIDEX's official website?

The official website for IRIDEX is www.iridex.com.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff